Javier Gómez

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

Rocio García‐Carbonero, Jeff Supko, Judith Manola et al. · Journal of Clinical Oncology · 2004 · 293 citations · Full text

Medicine, Oncology, Pharmacology +13

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

Chris Twelves, Klaas Hoekman, A. Bowman et al. · European Journal of Cancer · 2003 · 84 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Apoptosis Induced by IL-2 Withdrawal Is Associated with an Intracellular Acidification

Angelita Rebollo, Javier Gómez, Ana Martı́nez de Aragón et al. · Experimental Cell Research · 1995 · 71 citations

Life Sciences, Cell Biology, Immunology +12